Originator and biosimilar tumor necrosis factor alpha (TNFα) antagonistic mAbs are used extensively in clinical settings to treat inflammatory bowel disease (IBD; e.g., Crohn's disease and ulcerative colitis), rheumatoid arthritis, and other chronic inflammatory associated disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis (11). This evidence concerns the gene TNF and Crohn disease.